GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tilray Brands Inc (TSX:TLRY) » Definitions » Debt-to-EBITDA

Tilray Brands (TSX:TLRY) Debt-to-EBITDA : -1.81 (As of Feb. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Tilray Brands Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Tilray Brands's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$157 Mil. Tilray Brands's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Feb. 2024 was C$493 Mil. Tilray Brands's annualized EBITDA for the quarter that ended in Feb. 2024 was C$-359 Mil. Tilray Brands's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 was -1.81.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Tilray Brands's Debt-to-EBITDA or its related term are showing as below:

TSX:TLRY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -24   Med: -2.53   Max: 5.02
Current: -3.75

During the past 12 years, the highest Debt-to-EBITDA Ratio of Tilray Brands was 5.02. The lowest was -24.00. And the median was -2.53.

TSX:TLRY's Debt-to-EBITDA is ranked worse than
100% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs TSX:TLRY: -3.75

Tilray Brands Debt-to-EBITDA Historical Data

The historical data trend for Tilray Brands's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tilray Brands Debt-to-EBITDA Chart

Tilray Brands Annual Data
Trend Aug14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.00 -6.31 -3.81 -2.53 -0.46

Tilray Brands Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 -3.31 -17.64 -14.10 -1.81

Competitive Comparison of Tilray Brands's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tilray Brands's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Tilray Brands's Debt-to-EBITDA falls into.



Tilray Brands Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Tilray Brands's Debt-to-EBITDA for the fiscal year that ended in May. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(303.135 + 494.545) / -1721.282
=-0.46

Tilray Brands's annualized Debt-to-EBITDA for the quarter that ended in Feb. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(156.809 + 493.375) / -359.072
=-1.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Feb. 2024) EBITDA data.


Tilray Brands  (TSX:TLRY) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Tilray Brands Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Tilray Brands's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Tilray Brands (TSX:TLRY) Business Description

Traded in Other Exchanges
Address
265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.